Dofetilide use is not associated with increased mortality in patients with left ventricular hypertrophy and atrial fibrillation.
Daniel G WannBrent S MedoffNoor-Ul-Huda A MehdiAhmet SezerFloyd W ThomaSuresh MulukutlaAditya BhonsaleNathan A EstesSamir F SabaSandeep K Jainnull nullPublished in: Journal of cardiovascular electrophysiology (2022)
In a propensity-matched cohort of 718 patients with AF and LVH, dofetilide was not associated with increased mortality at 3 years. Our study adds to prior data demonstrating the safety of dofetilide in this population despite guideline recommendations against its use. Given the limited options for AF management in LVH patients, dofetilide may be reasonable for symptomatic AF management.
Keyphrases
- atrial fibrillation
- left ventricular
- end stage renal disease
- left atrial
- heart failure
- cardiovascular events
- oral anticoagulants
- catheter ablation
- ejection fraction
- newly diagnosed
- chronic kidney disease
- left atrial appendage
- direct oral anticoagulants
- peritoneal dialysis
- risk factors
- electronic health record
- percutaneous coronary intervention
- type diabetes
- mitral valve
- coronary artery disease
- machine learning
- acute coronary syndrome